Latest Breaking News On - Sekar kathiresan - Page 8 : comparemela.com

Crispr offers hope for a one-time cholesterol drug

Initial data from a human clinical trial suggests an experimental drug from Verve Therapeutics that uses gene editing to permanently lower cholesterol raises hopes that people can one day trade daily lipid-lowering pills for a one-time treatment

United statesDonald lloyd jonesSekar kathiresanNorthwestern universityDrug administrationAmerican heart associationVerve therapeuticsChief executive officer sekar kathiresanClinical drug trialExperimental drug

First trial of base editing in humans lowers cholesterol — but raises safety concerns

Super-precise gene-editing approach switches off a gene in the liver that regulates ‘bad’ cholesterol. Super-precise gene-editing approach switches off a gene in the liver that regulates ‘bad’ cholesterol.

United statesNew zealandUnited kingdomSekar kathiresanMichael torresLuigi naldiniLos angelesKarol watsonDavid liu at harvard university in cambridgeAmerican heart associationDrug administrationSteve gschmeissner science photo librarySalute san raffaele universityUniversity of pittsburghUniversity of californiaScience photo

Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a Loop

Data showed that a single infusion of Verve's genetic treatment led to drops of 40% to 55% in the “bad” LDL cholesterol.

United statesMyles minterDavid liuSekar kathiresanWilliam blairAmerican heart associationDrug administrationRegeneron pharmaceuticalsVerve therapeuticsNobel prize winningEli lillySeamus fernandezBeam therapeuticsBill alpertArticle normalBiotechnology services

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of.

United kingdomUnited statesNew yorkNew zealandSekar kathiresanAndrew bellingerJen robinsonAshlea kosikowskiDeepakl bhattSafety profile supports continued developmentCompany to host conference callExchange commissionVerve therapeutics incDrug administrationIcahn school of medicineObserved after

Daily statins taken by millions could be replaced by remarkable new gene therapy that cuts bad cholesterol by up to 50% with a SINGLE dose, scientists claim as they hail brave new world of heart treatment

Daily statins taken by millions could be replaced by remarkable new gene therapy that cuts bad cholesterol by up to 50% with a SINGLE dose, scientists claim as they hail brave new world of heart treatment
businesstelegraph.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstelegraph.co.uk Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKarol watsonAndrew bellingerSekar kathiresanBarney calmanAmerican heart associationScientific sessionsProfessor karol watsonStock imageVerve therapeutics